← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Apovax, Inc.
Louisville, KY
$4,911,595
Total funding
7
Grants
Funding over time
peak $1.3M · FY2006–11$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$4,911,595 · 7
By mechanism
R43$1,960,572 · 4
R44$1,771,799 · 1
R41$1,179,224 · 2
Investigators at Apovax, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
ApoVax104-HPV as a Novel Vaccine for Cervical Cancer$919,441
R44 · FY2008 · AI
ApoVax104-HPV as a Novel Vaccine for Cervical Cancer$852,358
R44 · FY2009 · AI
ApoVax104-TB as a Novel Vaccine for Tuberculosis$429,811
R43 · FY2009 · AI
ApoFasL: a Novel Immunotherapeutic for T1D$421,676
R43 · FY2007 · DK
Chimeric CD80-SA as a Novel Cancer Vaccine$417,413
R43 · FY2006 · CA
ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates$403,924
R41 · FY2010 · DK
ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates$399,912
R41 · FY2011 · DK
ApoVax104-TB as a Novel Vaccine for Tuberculosis$391,672
R43 · FY2008 · AI
ApoVax-SVN as a Novel Vaccine for Cancer Immunotherapy$328,300
R41 · FY2007 · CA
ApoVax104-HPV as a Novel Vaccine for Cervical Cancer$300,000
R43 · FY2007 · AI
ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates$47,088
R41 · FY2011 · DK